1 Correction to: Drug Saf https://doi.org/10.1007/s40264-018-0642-6
In the original publication of the article, the ALT and AST values in Fig. 5a–e were capped at 10× ULN, which did not accurately reflect the narrative provided for each case. In this correction, the original Fig. 5a–e (Fig. 1a–e) and the correct Fig. 5a–5e (Fig. 2a–e) are published.
Fig. 1a–e Original version of Fig. 5a–e as published on 28 February 2018
Fig. 2a–e Corrected version of Fig. 5a–e
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Marcinak, J.F., Munsaka, M.S., Watkins, P.B. et al. Correction to: Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience. Drug Saf 41, 1431–1437 (2018). https://doi.org/10.1007/s40264-018-0745-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40264-018-0745-0